Targets › AVPR1A
8 programs from 8 companies in 21 trials: 9 Phase 3, 5 Phase 4, 4 Phase 2, 3 Phase 1; Metabolic and endocrine, Genitourinary, Other; next expected readout Jan 2027.
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. (UniProt, P37288)
Open in Phaseline: the race on AVPR1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tiohundra | Vasopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Vasoplegic Syndrome of Cardiac Surgery; Retained Products of Conception; Shock … | Jan 2027 |
| Hamilton Health Sciences Corporation | Desmopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Chronic Kidney Diseases | Feb 2027 |
| Assistance Publique - Hôpitaux de Paris | Desmopressin Acetate Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Hyponatremia | Dec 2027 |
| Centre Hospitalier Universitaire Dijon | Argipressin Vasopressin V1a receptor agonist | AVPR1A | Phase 3 | Patients With Norepinephrine-refractory Vasoplegic Shock | Jan 2029 |
| Medical University of Bialystok | Desmopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Kidney Biopsy | – |
| Newleos Therapeutics | NTX-1472 V1a receptor antagonist | AVPR1A | Phase 2 | Social Anxiety Disorder (SAD) | Jan 2027 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Desmopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 2 | Cushing Syndrome | Oct 2028 |
| PharmaIN | Terlipressin (PHIN-214) Vasopressin V1 receptor binding agent; Vasopressin V2 receptor binding agent | AVPR1A, AVPR1B, AVPR2 | Phase 1 | Cirrhosis, Liver | – |
Sepsis (2) Septic Shock (2) Hyponatremia (1) Kidney Biopsy (1) Patients With Norepinephrine-refractory Vasoplegic Shock (1) Cushing Syndrome (1) Chronic Kidney Diseases (1) Cirrhosis, Liver (1) Social Anxiety Disorder (SAD) (1) Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial (1) Vasoplegic Syndrome of Cardiac Surgery (1) Retained Products of Conception (1)
small molecule (8)
Assistance Publique - Hôpitaux de Paris (1) Medical University of Bialystok (1) Centre Hospitalier Universitaire Dijon (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Hamilton Health Sciences Corporation (1) PharmaIN (1) Newleos Therapeutics (1) Tiohundra (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.